Inhibition of 20-kDa myosin light chain exchange by monoclonal antibodies against 17-kDa myosin light chain  by Higashihara, Masaaki & Ikebe, Mitsuo
FEBS 15352 FEBS Letters 363 (1995) 57-60 
Inhibition of 20-kDa myosin light chain exchange by 
monoclonal antibodies against 17-kDa myosin light chain 
Masaaki Higashihara”,“, Mitsuo Ikebeb 
“First Department of Internal Medicine, Faculty of Medicine, Vniversity of Tokyo, 7-3-l Hongo, Bunkyo-ku, Tokyo 113, Japan 
bDepartment of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH 44106, USA 
Received 7 February 1995; revised version received 8 March 1995 
Abstract Two anti-17,000 Da myosin light chain (LC17) mono- 
clonal antibodies (MM2 and MMlO), which increase the actin- 
activated Mg’+-ATPase activity of dephosphorylated smooth 
muscle myosin, inhibited the exchange of the 20,000 Da regula- 
tory light chain of myosin (LC20). MM2, which shows higher 
potency of activation of ATPase activity, inhibited the exchange 
more extensively than MMlO, suggesting that there is a correla- 
tion between the activation of ATPase activity and the inhibition 
of the LC20 exchange. The inhibition of the exchange was ob- 
served for intact myosin and heavy meromyosin but not suhfrag- 
ment 1, suggesting that the heavy chain at the head-rod junction 
is involved in the inhibition of LC20 exchange by anti-LC17 
antibodies. Alternatively, the interaction between the two heads 
of the myosin molecule may influence the inhibition of LC20 
exchange. These results suggest that LC20 interacts with both 
LC17 and the heavy chain, and the interaction between LC20 and 
LC17 is involved in the activation of actin-activated ATPase 
activity of smooth muscle myosin. 
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1. Introduction 
The motor activity of actomyosin from vertebrate smooth 
muscle and non-muscle cells is regulated by the phosphoryla- 
tion of the 20,000 Da (20-kDa) light chain (LC20) of myosin 
[ 1,2]. The phosphorylation site responsible for the regulation is 
Ser-19 of LC20 which is catalyzed by Ca’+/calmodulin depend- 
ent myosin light chain kinase (MLCK). Recent analysis of the 
crystal structure of skeletal muscle myosin subfragment-l (S-l) 
[3] and the regulatory domain of scallop myosin [4] revealed 
that this class of light chain is associated with myosin heavy 
chain at the head-rod junction. While the molecular mecha- 
nism by which the phosphorylation of LC20 regulates acto- 
myosin motor activity is not understood, it is plausible that the 
conformational change of LC20 induced by phosphorylation 
is transmitted to the heavy chain either directly or via the 17,000 
Da (17-kDa) light chain (LC17) which ultimately affects the 
effector sites of myosin located at the top of the head. The 
change in LC20 conformation could first be transmitted to the 
heavy chain at the headdrod junction. 
We have hypothesized [S-9] that phosphorylation of LC20 
induces the change in the conformation at the head-rod junc- 
tion of myosin and this is involved in the regulation mechanism 
of smooth muscle actomyosin motor activity because: (i) S-l, 
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but not heavy meromyosin (HMM), containing intact light 
chains fails to show phosphorylation dependence on its actin- 
activated ATPase, suggesting that the head-rod hinge region 
plays a role in the regulation [5]; (ii) LC20 phosphorylation 
changes the conformation at the head-rod junction which is 
indicated by several experimental observations, i.e. increase in 
the digestibility at the head-rod junction [6], increase in the 
flexibility at the hinge region [7], and change in the head orien- 
tation observed by electron microscopy [8,9]. 
While the regulatory function of LC20 in the smooth muscle 
actomyosin system is well documented, the function of LC17 
is not clear. Previously, we reported that a monoclonal anti- 
body which recognizes LC17 can activate the actin-activated 
ATPase activity of myosin without LC20 phosphorylation [lo]. 
This suggested that LC17 might be involved in the regulatory 
mechanism of phosphorylation-induced activation of acto- 
myosin. Recent structural analysis of the scallop myosin regula- 
tory domain revealed [4] that the N-terminal domain of the 
essential light chain (corresponding to LC17) interacts with the 
regulatory light chain (corresponding to LC20) which stabilizes 
Ca*’ binding to the N-terminal domain of the essential light 
chain so as to regulate actomyosin ATPase activity. On the 
other hand, it is not known whether or not LC20 and LC17 
interact with each other and thus contribute to the transmission 
of phosphorylation-induced signal to the effector sites. 
In the present study, we examined the interaction between 
LC20, LC17 and the heavy chain of smooth muscle myosin 
using specific monoclonal antibodies as probes. 
2. Material and methods 
2.1. Materials 
Smooth muscle myosin and myosin light chain kinase were prepared 
from turkey gizzard [ll]. Heavy meromyosin (HMM) and subfrag- 
ment-1 (S-l) were prepared by digestion of myosin by Staphylococcus 
aureus protease (SAP) as described previously [5].- Phosphorylated 
LC20 was prepared as described previously [12]. Calmodulin was pre- 
pared from bull testes according to Walsh et al. [13]. 
2.2. Production of monoclonal antibodies against smooth muscle myosin 
Balb/c mice were immunized with intact smooth muscle myosin. 
Screening and purification of antibodies were performed as described 
elsewhere [lo]. IgG monoclonal antibodies (MM6, MM9 and MMlO) 
were purified using a protein A column, and IgM monoclonal antibody 
(MM2) was purified using DEAE-Sepahacel after tryptic digestion [lo]. 
2.3. LC20 exchange 
An 8 to 10 molar excess of LC20 phosphorylated with [y-‘*P]ATP 
(P-LC20) was added to the sample; intact myosin (0.5 mg/ml), 0.5 M 
NaCl, 30 mM Tris-HCI, pH7.5, in the presence of 1 mM EDTA or 
1 PM MgZC (Ca*‘-EDTA buffer) and incubated at 40°C for 30 min, with 
or without monoclonal antibodies. To investigate the role of the S-US-2 
junction, HMM or S-l was substituted for intact myosin. Samples were 
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Fig. 1. Elution profile with a SW3000 HPLC column. Radioactivity (0, A) or protein concentration (0, A) was shown. LC20 exchange was performed 
with (A, A) or without (0, ??) monoclonal antibody (lOpg/ml). Fraction 25, 34 and 53-54 indicates intact myosin, MM2 antibody or phosphorylated 
LC20, respectively. Inset shows urea gel-electrophoresis; control myosin (lane a) or myosin fraction exchanged by phosphorylated LC20 in the absence 
(lane b) or presence (lane c) of MM2 antibody. Specific activity was about 100,000 cpm/l nmol ATP. 
then applied to a SW3000 HPLC column (Toso Co., Japan). Radioac- 
tivities in the fractions of myosins, HMM, S-l or LC20 were counted 
and protein concentrations of their fractions were measured. The extent 
of exchange was calculated according to the following formula: 
Extent of exchange (%) = (n + 1)/n x A/B x C/2D x 100 
where n = exogenous phosphorylated LC20/endogenous LC20, 
A = amount of the exogenous LC20 in myosin or myosin fragments, 
B = amount of myosin or myosin fragments, C = molecular weight of 
myosin or myosin fragments, and D = molecular weight of LC20. 
2.4. Others 
Urea gel-electrophoresis was performed by the method of Perrie and 
Perry [14]. Protein concentration was measured by the method of 
Bradford [15]. 
3. Results and discussion 
The interaction of LC20 with myosin was monitored by 
measuring the LC20 exchange efficiency. To measure the extent 
of LC20 exchange, the isolated LC20 was first phosphorylated 
by MLCK and incubated with myosin at high temperature to 
accomplish LC20 exchange [7] (also see section 2). Myosin 
exchanged with exogenous radiolabeled LC20 eluted faster 
than unbound LC20; efficiency of LC20 exchange was deter- 
mined according to the radioactivity of LC20 incorporated in 
myosin. As shown in Fig. 1, the radioactivity of LC20 coeluted 
with the myosin fraction; urea gel-electrophoresis of the frac- 
tion revealed that the LC20 of myosin was almost completely 
exchanged with exogenous phosphorylated LC20 (Fig. 1, inset 
lane b). The extent of exchange (%) (see section 2) was calcu- 
lated as 95-100% in the presence of 1 mM EDTA and about 
70% in the presence of 1 PM MgCl,. 1 mM MgCl, almost 
completely inhibited the LC20 exchange. On the other hand, 
when LC20 exchange was performed in the presence of MM2, 
which recognizes LC 17 [lo], the incorporation of the exogenous 
LC20 indicated by radioactivity was markedly diminished (Fig. 
1). The decrease in exchangeability was also confirmed by urea 
gel-electrophoretic analysis which showed a marked decrease 
in the exogenous phosphorylated LC20 incorporated into 
myosin (Fig. 1, inset lane c). Using this method, we examined 
the inhibition of LC20 exchange by monoclonal antibodies 
which recognize various regions of the myosin molecule, i.e. 
MM2 and MM10 which recognize LC17 [lo], MM9 which 
recognizes S-2 near the S-l/S-2 junction [16], and MM6 which 
recognizes the head portion of myosin [lo]. Table 1 shows the 
% inhibition of LC20 exchange by monoclonal antibodies in the 
presence of 1 mM EDTA or 1 PM MgCl,. MM2 inhibited the 
LC20 exchange most dramatically while MM6, which recog- 
nizes the 68-kDa N-terminal fragment of S- 1, the top of myosin 
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Table 1 
Percent inhibition of LC20 exchange” 
Condition of exchange MM-2 MM-10 MM-9 MM-6 
Intact HMM S-l Intact HMM S-l Intact HMM S-l Intact 
1 mM EDTA + 1 mM ATP 
(84: 
ND ND ND ND 
(:) 
1 ,uM Mg*’ + 1 mM ATP 
(K :3) :) p2) 
ND, not done; intact, intact myosin; HMM, heavy meromyosin; S-l, subfragment-1. 
“{extent of exchange(- McAb) - extent of exchange(+ McAb)} /extent of exchange(-McAb). Extent of exchange was determined as described in 
section 2. 
*Value shows the mean of 2-5 experiments. 
**Values indicate the number of experiments. 
S-l head according to the three-dimensional structure of S-l [3], 
did not inhibit the exchange at all. MMlO, which also recog- 
nizes LC17, inhibited the LC20 exchange but to a lesser extent. 
This is probably due to the difference in the epitopes of the two 
antibodies. MM9 inhibited the exchange but the inhibition was 
significantly less potent than LC17 recognizing antibodies. 
Table 2 shows the effects of various antibodies on the actin- 
activated ATPase activity of dephosphorylated myosin [10,16]. 
Antibodies except MM6 activated the ATPase activity and the 
extent of activation was MM2 > MM10 > MM9. The point of 
interest is that the inhibition efficiency of the antibodies against 
LC20 exchange is closely correlated to the extent of activation 
of ATPase activity of myosin. Another important point is that 
none of the antibodies inhibited the LC20 exchange of S- 1 while 
the inhibition of LC20 exchange for HMM was found to be 
virtually the same as intact myosin (Table 1). Corresponding 
to this observation, it was found that all of the antibodies failed 
to activate acto-Sl ATPase activity (not shown). 
Recently it was found that deletion of the C-terminal residues 
of LC20 decreases the affinity of LC20 for heavy chain [ 171, and 
the region critical for the binding to heavy chain was assigned 
to be LYS’~~ -Ala’66 [17]. This suggests that the major anchoring 
site of LC20 to myosin via the LC20-myosin heavy chain inter- 
face localizes to the C-terminal domain of LC20. Therefore it 
is likely that the antibodies strengthened the interaction be- 
tween LC20 and the heavy chain so as to reduce the exchange- 
ability. The most dramatic inhibition of LC20 exchange was 
observed with anti-LC17 antibodies and this is of our interest. 
Three-dimensional structure analysis of the skeletal muscle 
S-l [3] and scallop myosin regulatory domain [4] revealed that 
Table 2 
The effect of McAb on the actin-activated ATPase activity of 
dephosphorylated myosin 
McAb Epitope VW,, K,,,,, 
(nmol/min mg) (mg/ml) 
_ 1.85 0.89 
MM2 LC17 23.85* 0.63* 
MM 10 LC17 9.62 0.55 
MM9 s-2 5.92** 0.45** 
MM6 S-l 2.02 0.85 
P-Myosin 25.56* 0.73* 
McAb, monoclonal antibody; P-Myosin, phosphorylated myosin; 
LC17, 17,000 Da myosin light chain; S-l, subfragment-1; S-2, subfrag- 
ment-2. 
*Higashihara et al. [lo]. 
**Higashihara et al. [16]. 
the C-terminal domain of regulatory light chain is in close 
proximity to the N-terminal domain of essential (alkali) light 
chain. Furthermore, it was revealed for scallop myosin that 
Gly ‘I7 in the C-terminal domain of the regulatory light chain 
interacts with the N-terminal residues of essential light chain 
[4]. Therefore, it is plausible that the binding of anti-LC17 
antibodies to LC17 changes the interaction between the N- 
terminal domain of LC17 and the C-terminal domain of LC20. 
An important finding is that such a change in the interaction 
is reflected by an activation of actomyosin ATPase activity. 
This view is supported by a recent finding that the elimination 
of LC17 significantly diminishes actomyosin motility [ 181. 
Quite recently, we found that the residue Lys’49pPhe’58 of LC20 
at the C-terminal domain are critical for the phosphorylation- 
induced activation of actomyosin ATPase activity [17]. To- 
gether with this information, it can be explained that anti-LC17 
antibodies activate the ATPase activity by altering the interac- 
tion between the C-terminal domain of LC20 and the N-termi- 
nal domain of LC17, which in turn changes the LC20-heavy 
chain interaction which is critical for the activation of actin- 
activated ATPase activity of smooth muscle myosin. The pres- 
ent results suggest that the interaction between LC17 and LC20 
is involved in the activation mechanism of smooth muscle 
myosin molecule. 
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